Revolutionising biomedical data sharing and AI-driven healthcare solutions

Illustration swith SEARCH initiative consortium members, including Benelux

Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.

hemotune AG Achieves ISO 13485 Certification, Advancing Breakthrough Nanotechnology in Blood Purification for Improved Patient Care

Proud hemotune AG team showing ISO 13485 certificate

Schlieren, Switzerland, August 24th 2023 – hemotune AG, a pioneering MedTech startup revolutionizing blood purification with cutting-edge nanotechnology, proudly announces its attainment of ISO 13485 certification. The certification covers design and development, production, distribution, and service of medical devices for blood purification including coated colloidal nanoparticles and marks a significant milestone towards delivering its innovative blood purification technology to patients.

Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA

HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.

Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally. 

hemotune recognized as innovation leader in blood purification technology

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally. 

Global Entrepreneurship Week 2022 – Basel

Increasing patients’ safety and care in research is vital when preparing and conducting your study. From a HEMEX perspective, we are tackling in this article four important points you should consider during the process.

Why do you need a European Authorised Representative?

The new Regulations for medical devices and in vitro diagnostic devices create a more robust, transparent, and sustainable regulatory framework. In this article, we will tell you all you need to know to be up to date to the new requirements implemented by the European Commission.